Proposal to widen access to existing medicines and fund a new medicine for the treatment of cystic fibrosis

Pharmac is seeking feedback on a proposal to widen access to Trikafta and Kalydeco and begin funding Alyftrek for the treatment of cystic fibrosis.

If approved, these medicines would be funded from 1 April 2026.

➤ Proposal to fund widen access to Trikafta and Kalydeco, and fund Alyftrek for the treatment of cystic fibrosis. 

We welcome your feedback. Consultation is open until 5pm Wednesday 11 February 2026. Please send your feedback to consult@pharmac.govt.nz or use the online form linked in the consultation

Ngā mihi

Matthew McKenzie | Senior Therapeutic Group Manager

Pharmac | Te Pātaka Whaioranga | PO Box 10 254 | Level 9, 40 Mercer Street, Wellington

P: 0800 660 050 | www.pharmac.govt.nz